Heranba Industries Ltd

- There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript from Heranba Industries Limited's Q3 and 9MFY23 earnings call. - The company discussed capex plans, with an expected capex of around INR 120 crores for FY23 (down from initial guidance of INR 150 crores), but no indication of how this capex is being financed. - Cash flow from operations is currently around neutral for the financial year, with slight negative expected in Q3, and aiming for positive or neutral by year-end, suggesting internal cash generation focus rather than external fundraising. - Management did not indicate any plans for raising fresh equity or debt during the call.

- Capex for 9 months FY23: Around INR 60 crores; total FY23 capex expected around INR 110-120 crores (INR 150 crores looks difficult). - Phase 1 of Sarigam facility commissioning targeted by end of Q4 FY23 (March end 2023), on track. - Sarigam Phase 1 to start with 2-3 molecules; Phase 2 to start post October 2023 with additional molecules. - Next stage of capex at Saykha planned by FY24 end, focused on herbicides. - Sarigam facility expected to generate 2.5x to 3x revenue on investment by FY25, ramp-up in phases. - Capex plans are progressing as planned to strengthen capacities and capabilities for coming years. - New plants will bring a different product portfolio targeting expanded geographies, diversifying product range.

- Heranba targets long-term revenue growth of 18% to 20% annually. - FY '23 seen as a challenging, transitionary year due to global macroeconomic issues, with revenue expected to match last year's INR 1,450 crores. - For FY '24, the company aims for INR 1,850 crores revenue, reflecting 18% to 20% growth. - Potential pent-up demand from FY '23 weakness might offer an upside, but management remains conservative on exceeding 20% growth next year. - New Sarigam facility Phase 1 to commission by March-end FY '23, expected to ramp up revenues by 2.5x to 3x investment by FY '25. - Expansion into new geographies (US, Middle East, China reopening) and product registrations to contribute to growth. - US business aims for $25 million revenue in 2-3 years, with 6-7 product registrations planned. - Domestic branded formulations grew ~25%-30%, indicating growth scope despite temporary technical sales decline.

- FY'23 is seen as a transition year with challenging global macros impacting performance. - Revenue for FY'23 expected to be flat or match last year's turnover (~INR 1,450 crores). - Long-term revenue growth guidance: 18% to 20% CAGR from FY'24 onwards. - EBITDA margin guidance for FY'24: around 18% to 20%; FY'23 EBITDA margin around 12% to 14%. - Net profit margins expected to improve with better cost controls and growing scale. - US business targeted to reach $25 million revenue in 2-3 years, driven by expanding product registrations. - Sarigam facility Phase 1 commissioning by Q1 FY'24 expected to boost capacity and product portfolio. - New plant capex and registrations expected to enhance growth and margin profile from FY'24. - Conservative outlook for pent-up demand with cautious optimism for exceeding 20% revenue growth in FY'24.

- The transcript does not explicitly mention the current or expected order book or pending orders in specific figures. - However, several points indicate the demand and order situation: - Q3 FY23 demand was weak due to global macroeconomic challenges, including China lockdowns and inflation issues. - Orders from China have started coming in after reopening, but demand is still cautious due to ample supply and lower price expectations. - Domestic demand in Q3 is usually low; herbicides see demand more in Q3, while Heranba's strong areas (insecticides and fungicides) traditionally see demand in Q4. - Some discussions reference increased inventory in channels indicating slower order movement. - Management remains optimistic about demand revival in Q4 and FY24 targeting 18%-20% revenue growth. - Overall, while exact order book data is not disclosed, demand is recovering cautiously with expected improvement in Q4 FY23 and FY24.